BioPorto and Phadia have reached a settlement in the case before the Supreme Court No. 206/2012 regarding the revocation of Phadia’s patent DK/EP 0756 708, which cites the use of HNL (another designation of NGAL) as a diagnostic marker of human illness.
Help employers find you! Check out all the jobs and post your resume.
